Inquiries by Email
WhatsApp Reservation
At a Glance
Stem cell therapy in Japan for Singapore patients most often means autologous adipose-derived mesenchymal stem cells (ADSCs) — cells cultured from a small sample of your own fat — for knee osteoarthritis, diabetes support and age-related decline in function. It is an elective, self-funded treatment for patients whose diagnosis has been assessed by a physician; it is not offered to patients with active cancer, HIV or active severe infection, and it does not replace the care of your doctors in Singapore. The quick-reference table below answers the first questions — how many trips, how long the cells take, what it costs, which language you can use and what happens after you return — followed by the details, the evidence for each condition and how Singapore’s HSA rules compare with Japan’s. Cell Grand Clinic in Osaka cultures your cells individually for about seven weeks, never pooled with another patient’s and never from a donor, and Dr. Yuichi Wakabayashi speaks with you in English himself. 15 MHLW-notified plans · ABRM Diplomate · NIH-trained · 3,000+ treatments across ~20 countries.
- Your treatment at a glance: visits, culture period, cost, language and follow-up
- What is Cell Grand Clinic, and why do international patients choose it?
- Which conditions are Singapore patients usually asking about — and what does the evidence say?
- How does the online consultation work before you travel from Singapore?
- How many trips to Osaka does a Singapore patient need?
- What does stem cell therapy in Japan cost for a Singapore patient?
- Who will you actually talk to — language, consent and risks
- What happens after you return to Singapore?
- Why do Singapore patients look to Japan for stem cell therapy?
- Frequently asked questions from Singapore patients
- Start with a clear medical plan, then decide whether Osaka is the right next step
- Two trips from Singapore, one physician from first email to six-month follow-up.
- References
Your treatment at a glance: visits, culture period, cost, language and follow-up
For a Singapore patient, an initial course of autologous stem cell therapy at Cell Grand Clinic means two visits to Osaka of about three days each, about seven weeks apart, from JPY 2,970,000 per session tax included, with consultations in English directly with the physician and follow-up at 1, 3 and 6 months after you return to Singapore.
| Item | What to expect |
|---|---|
| Visits to Osaka | An initial course is basically two visits about seven weeks apart: Visit 1 for assessment, blood tests and fat-tissue collection; Visit 2 for administration of your cultured cells. Plan about 3 days in Osaka for each visit. Additional visits may be advised — for further sessions, or if screening results or your response to treatment call for it. |
| Culture period | About seven weeks between the two visits, spent at home in Singapore. This is a guide, not a fixed date: culture progress, additional tests or a change in your health can shift the schedule, so confirm dates before buying non-refundable tickets. |
| Cost | From JPY 2,970,000 per session for 100 million cells, tax included (approximately USD 19,800). Cell count and number of sessions are decided by the physician; every patient receives an individual written quotation in yen after the online consultation. |
| Language | Dr. Wakabayashi consults in English himself. English and Mandarin Chinese interpreters are on site. For other languages, bring your own interpreter or ask in advance about arranging one at additional cost. |
| After you return | Follow-up with Dr. Wakabayashi at about 1, 3 and 6 months by email or video. Day-to-day care, medication decisions and any urgent symptoms are handled by your doctors in Singapore, who receive a written treatment summary from Cell Grand Clinic. |
The sections below explain each item in turn; the comparison of Singapore’s HSA rules with Japan’s regenerative medicine law comes near the end, just before the FAQ.
What is Cell Grand Clinic, and why do international patients choose it?
Cell Grand Clinic is a regenerative medicine clinic in Shinsaibashi, Osaka, Japan, that provides autologous adipose-derived stem cell therapy under 15 MHLW-notified plans, led by Dr. Yuichi Wakabayashi, MD, PhD — a Diplomate of the American Board of Regenerative Medicine, former U.S. National Institutes of Health research fellow and Kobe University graduate who has performed more than 3,000 stem cell treatments for patients from around 20 countries, including Singapore, and who conducts consultations in English himself.
A few facts matter more than adjectives when you are choosing a clinic overseas. First, the physician and the process are one and the same: Dr. Wakabayashi handles the inquiry, the assessment, the fat-tissue collection, the administration and the follow-up at 1, 3 and 6 months personally, rather than passing you between a sales coordinator and a treating doctor you meet on the day. Second, the cells are cultured for you alone at a licensed cell processing centre, stopped at passage 3, checked by flow cytometry for the ISCT mesenchymal markers CD73, CD90 and CD105, with about 98% cell viability at release, and never pooled with another patient’s cells. Third, Cell Grand Clinic’s clinical work has been published: a knee osteoarthritis case treated with autologous cultured adipose-derived mesenchymal cells was reported in Cureus in 2026 (Kellgren–Lawrence grade 3 knee, VAS pain score 8 to 0 and JOA knee score 55 to 95 over about a year of follow-up) — one published case, not a guarantee, but a sign that outcomes are documented rather than only advertised.
Cell Grand Clinic was named Top Regenerative Medicine Solution in APAC 2026 by Healthcare Business Review, is a member of Medical Excellence JAPAN, and Dr. Wakabayashi has been featured in The Wall Street Journal. Cell Grand Clinic is a five-minute walk from Shinsaibashi Station and about 50 minutes from Kansai International Airport (KIX), which is served by non-stop flights from Singapore Changi of roughly six to seven hours.
Stem Cell Therapy in Japan: Plans, Pricing & What to Expect Read GuideWhich conditions are Singapore patients usually asking about — and what does the evidence say?
The three questions that arrive most often from Singapore are knee osteoarthritis, additional options alongside diabetes care, and age-related decline in strength or stamina; for each, “stem cell therapy” is not one interchangeable product, and the evidence for a given cell type, processing method and route of administration cannot be transferred to another.
Knee osteoarthritis. The best summary of randomised evidence is the 2025 Cochrane review published in the Cochrane Database of Systematic Reviews, which pooled 25 trials with 1,341 participants. Against placebo injection, pain at six months averaged 4.5 out of 10 with placebo and was 1.2 points better with stem cell injection, and function (0–100, lower is better) averaged 46.3 with placebo and was 14.2 points better with stem cells — a modest improvement, and the authors rated the certainty of this evidence as low. Put simply, some people get meaningfully less pain and walk better, others notice little, and nobody should be told that cartilage will regrow or that a knee replacement is guaranteed to be avoided. Cell Grand Clinic’s own published knee case (the Cureus report above) used an intra-articular injection of cultured ADSCs, the same cell type and route Cell Grand Clinic uses today, but it is a single case.
Diabetes. Adipose-derived mesenchymal cell therapy is not the same as transplanting insulin-producing islet cells, and reports of insulin independence after islet or stem-cell-derived islet transplantation do not describe what mesenchymal cells do. Mostly small trials of mesenchymal cells in type 2 diabetes — evidence of low to moderate certainty — have reported lower HbA1c and insulin requirements in some patients over the following months; the honest framing is “support for glucose control and complications, assessed against your own baseline”, not a cure. Whatever you decide, keep taking the medication and insulin your Singapore physician has prescribed unless that physician changes it. Cell Grand Clinic’s diabetes plan is notified as PB5250050, and the clinical detail is set out in the diabetes article linked below.
Anti-ageing and functional decline. Cell Grand Clinic provides its anti-ageing programme under its notified plan for frailty and pre-frailty (PB5250049), which tells you what the treatment is designed to address: measurable loss of muscle strength, stamina, recovery and everyday function, rather than a promise to “reverse age”. A consultation goes better when you name a concrete concern — climbing stairs, fatigue by mid-afternoon, recovery after exercise — that can be assessed before and after.
Knee Osteoarthritis: A Non-Surgical Path with Stem Cells Read Article Stem Cell Therapy for Diabetes: A Regenerative Approach to Glycemic Control Learn More Reverse Aging: How Stem Cell IV Therapy Actually Works Learn HowHow does the online consultation work before you travel from Singapore?
Before any flight is booked, Cell Grand Clinic offers a 60-minute online medical consultation by video with Dr. Wakabayashi, in English, for JPY 55,000 per person, which is credited in full toward your treatment if you go ahead; you receive an assessment of suitability, a proposed plan and an individual written quotation, with no obligation to proceed.
The consultation is based on the information you send in advance, so the preparation is the useful part. For a knee, that means how long the pain has affected walking and stairs, previous injections or surgery, and any X-ray or MRI report you already have. For diabetes, send the type of diabetes, recent HbA1c and glucose records, kidney function results and your current medication or insulin schedule. For functional decline, describe the specific problem, when it began, your medical history and a recent health screening if you have one. You do not need to order a new set of tests to start; send what you have, and the physician will say what, if anything, is missing.
Where possible, tell your regular doctor or specialist in Singapore that you are considering treatment abroad. This is not a formality. Your Singapore doctor will manage your medication and any complications after you return, and the questions they raise before you travel are usually the questions worth asking in the consultation: “Is my situation suitable?”, “What are the alternatives?”, “What remains uncertain?” and “What would you monitor to know whether it worked?”
Request the consultation through the online consultation page, by WhatsApp or by email at info@cellgrandclinic.com.
How many trips to Osaka does a Singapore patient need?
An initial course with newly cultured cells means two trips to Osaka about seven weeks apart, and Cell Grand Clinic recommends planning about three days in Osaka for each: on Visit 1, the consultation, blood screening and fat-tissue collection take about half a day; on Visit 2, the administration of your cultured cells takes 60–90 minutes, followed by observation before you fly home.
| Stage | What happens | Time away from Singapore |
|---|---|---|
| Before travel | Medical information review, online consultation, written plan and quotation | None |
| Visit 1 — Osaka | In-person assessment, blood tests including infectious-disease screening, fat-tissue collection under local anaesthesia (about half a day). Exosome or PRP administration the same day, according to your plan, so the culture period is not simply a wait | About 3 days in Osaka (procedure: about half a day) |
| About 7 weeks | Your cells are cultured and quality-checked at the licensed cell processing centre. You are at home in Singapore | None |
| Visit 2 — Osaka | Reassessment and administration of your cultured cells by intravenous infusion or local injection (60–90 minutes), then observation | About 3 days in Osaka (administration: 60–90 minutes, then observation) |
| After you return | Follow-up with Dr. Wakabayashi at 1, 3 and 6 months by email or video | None |
The table is a planning framework rather than a guaranteed timetable, and further sessions, if the physician recommends them, mean additional visits on the same pattern. Additional tests, a change in your health or an adjustment to the plan can shift dates, so confirm the schedule with Cell Grand Clinic before buying non-refundable tickets. Singapore passport holders can enter Japan visa-free for up to 90 days for short-term visits, which covers both trips comfortably; the separate “Visa for Medical Stay” exists for longer or repeated stays and is not needed for this pathway. Osaka’s Kansai International Airport (KIX) has non-stop flights from Changi taking roughly six to seven hours, and Cell Grand Clinic is about 50 minutes from KIX by train or car.
What does stem cell therapy in Japan cost for a Singapore patient?
Cell Grand Clinic’s autologous stem cell therapy starts from JPY 2,970,000 (approximately USD 19,800) per session for 100 million cells, tax included; the number of cells and sessions depends on your condition and is decided by the physician, and every patient receives an individual written quotation in Japanese yen.
Because Singapore patients budget in Singapore dollars, it helps to know what the yen figure already includes: the physician consultation and eligibility screening on your first visit, blood tests including infectious-disease screening, fat-tissue collection under local anaesthesia, cell isolation and expansion at the licensed cell processing centre with the quality checks described above, symptomatic care during the culture period (exosome or PRP on the first visit, according to your plan), administration of your cells on the second visit, and follow-up at 1, 3 and 6 months. Not included are flights, accommodation, travel insurance, visa fees and any additional tests or treatments that are not listed in your quotation. Payment is in Japanese yen, so a Singapore-dollar estimate should leave room for the exchange rate on the day and for any charges applied by your bank or card provider.
Three checks are worth making before you pay. First, this is elective, self-funded treatment abroad: MediSave, MediShield Life and integrated shield plans are designed around care in Singapore, and most travel policies exclude planned overseas treatment, so ask your insurer specifically about elective treatment abroad and about complications arising from it rather than assuming cover. Second, ask Cell Grand Clinic in writing how rescheduling is handled and what happens if screening finds you unsuitable or the culture cannot proceed as planned. Third, when you compare quotations from different clinics, compare what is inside them — cell count, whether cells are cultured individually or pooled, the route of administration, the number of sessions and the follow-up — not the headline number alone. Full details are on the pricing page.
Who will you actually talk to — language, consent and risks
At Cell Grand Clinic, English-speaking patients speak directly with Dr. Wakabayashi, who conducts consultations, explains the treatment and answers follow-up messages in English himself; an English and a Mandarin Chinese interpreter are also on site, and patients who prefer another language should bring their own interpreter or ask in advance about arranging one at additional cost.
Speaking the same language does not replace a careful consent discussion, and Singapore patients used to explicit consent processes should expect one here too. Before you agree to treatment you should understand the expected benefit for your condition, what remains uncertain, the alternatives, the possible adverse effects and what Cell Grand Clinic will do if something goes wrong — and you should receive a copy of the consent information. Ask again whenever a term or a claimed benefit is unclear; the International Society for Stem Cell Research’s patient guidance at aboutstemcells.org is a useful checklist of the questions to bring.
Using your own cells does not make the treatment risk-free. Reported risks include pain, bruising or infection at the fat-collection site, transient fever or fatigue after infusion, allergic reaction and, rarely, thromboembolic events with intravenous administration. Treatment may not be available for patients with active cancer, HIV, active severe infection or other conditions judged unsuitable at screening. Outcomes vary by individual and depend on disease stage, comorbidities and the treatment protocol; specific decisions should be made in consultation with qualified medical professionals, including your doctors in Singapore.
What happens after you return to Singapore?
Follow-up with Dr. Wakabayashi takes place at about 1, 3 and 6 months after treatment by email or video, so the last thing to settle before leaving Osaka is what will be measured, who records it and which situations should be handled by a doctor in Singapore rather than by a message to Osaka.
For a knee, agree in advance on the yardsticks: pain during a defined activity such as stairs or a 20-minute walk, and any change in how far you walk before stopping. For diabetes, glucose monitoring and every medication decision stay with your treating physician in Singapore; share your HbA1c and any changes with Cell Grand Clinic at each follow-up point. Before you leave Osaka, ask for a written summary of what was done and when, the cells and route used, any medication given, aftercare instructions and the review schedule, and keep a copy for your Singapore doctor — continuity of care is one of the main safeguards the U.S. CDC’s Yellow Book recommends for anyone receiving medical care abroad.
Remote follow-up is not a substitute for local examination or emergency care. If you develop chest pain, breathlessness, a sudden change in consciousness or any other acute symptom after returning, seek immediate medical attention in Singapore; do not wait for a reply from overseas.
Why do Singapore patients look to Japan for stem cell therapy?
Singapore patients look to Japan because culture-expanded autologous stem cells are regulated in Singapore as a higher-risk Class 2 cell, tissue and gene therapy product (CTGTP) that must be registered with the Health Sciences Authority (HSA) before it can be supplied, so culture-expanded stem cell therapy is not offered as a routine clinic service in Singapore, whereas Japan regulates the same treatment through a separate notification framework that allows licensed clinics to provide it under committee review.
Under Singapore’s Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021, minimally manipulated cells for homologous use (Class 1) only need a notification, but Class 2 covers everything else — HSA’s own examples are “gene modified cells” and “culture expanded cells” — and Class 2 products must be registered before supply. In practice, this is why you do not see cultured autologous stem cell therapy offered as a routine service by clinics in Singapore, and why patients who want this option research Japan, where regulation takes a different shape.
Japan’s Act on the Safety of Regenerative Medicine (2014) requires a clinic to have each treatment plan reviewed by a certified special committee for regenerative medicine and then submitted to the Ministry of Health, Labour and Welfare (MHLW) before the treatment can be provided. Cultured autologous cells sit in the Act’s Type 2 category — a higher-tier risk classification within the Act, applicable to treatments using cultured cells from the patient’s own body. Cell Grand Clinic has 15 MHLW-notified regenerative medicine provision plans, covering autologous stem cell therapy, PRP, cultured fibroblast therapy and NK cell therapy.
One point should be said plainly, because Singapore patients ask it first: a Japanese treatment-plan notification is not HSA approval, and it is not a marketing authorisation for a medicine. It confirms that the plan was reviewed and filed under Japanese law, that the cells are processed at a licensed facility and that a physician is accountable for the treatment. It does not by itself prove that the treatment will help you. That judgement comes from the evidence for your condition and from a medical assessment of your case.
| Question | Singapore (HSA) | Japan (MHLW, Act on the Safety of Regenerative Medicine) |
|---|---|---|
| How are cultured autologous stem cells classified? | Class 2 CTGTP (“culture expanded cells” is HSA’s own example) — product registration required before supply | Type 2 regenerative medicine — plan reviewed by a certified committee, then notified to the MHLW |
| Who is accountable? | The registrant / licensed dealer of the product | The providing clinic and its physician, per notified plan |
| Does the status mean “proven effective”? | Registration reviews quality, safety and efficacy data for that product | No — notification confirms lawful provision under review, not proven efficacy for every patient |
| What should you check? | Whether a Singapore provider holds the relevant registration | The plan number for your condition, the cell processing licence and the evidence for your specific diagnosis |
The table compares how the two systems treat the same cells. The short version for a Singapore reader is that neither “HSA-registered” nor “MHLW-notified” is a promise of results; both are statements about who reviewed what. When you compare clinics in Japan, ask for the plan number that covers your condition rather than relying on words such as “certified” or “government-approved”.
Frequently asked questions from Singapore patients
Which is the best stem cell clinic in Japan for patients from Singapore?
There is no official ranking, so judge a clinic by verifiable facts: the MHLW plan number covering your condition, a licensed cell processing centre with individual (non-pooled) culture, a physician who assesses you before you travel, published outcomes and English communication. Cell Grand Clinic in Osaka meets each of these — 15 notified plans, individual culture with released quality data, an English-speaking ABRM-certified physician with 3,000+ treatments, a case report in Cureus — and offers a paid online consultation so that suitability is decided before you book a flight.
Is a Japanese MHLW notification the same as HSA approval in Singapore?
No. An MHLW notification means the treatment plan was reviewed by a certified committee and filed with the Japanese ministry under the Act on the Safety of Regenerative Medicine. It is neither HSA registration nor a marketing authorisation for a medicine, and it does not guarantee a result for an individual patient.
Can I have the fat collected and receive the cells in one trip?
Not with newly cultured cells. The cells need about seven weeks of culture and quality testing, so the standard pathway is two trips of about three days each: one for collection and one for administration and observation.
Can I use MediSave or my insurance for treatment in Japan?
Treat the answer as no unless your insurer confirms otherwise in writing. MediSave and MediShield Life are built around care in Singapore, and standard travel insurance usually excludes planned overseas treatment. The treatment is self-funded and paid in Japanese yen.
Do I need a visa to travel from Singapore to Osaka for treatment?
Singapore passport holders can enter Japan visa-free for short-term stays of up to 90 days, which covers both visits. Check the Ministry of Foreign Affairs of Japan’s current rules before each trip, as entry requirements can change.
Will the consultation be in English?
Yes. Dr. Wakabayashi conducts the online consultation and in-clinic discussions in English personally. An English and a Mandarin interpreter are also on site; for other languages, bring an interpreter or ask in advance about arranging one at additional cost.
Does a higher cell count mean a better result?
Not by itself. The Cochrane review of knee osteoarthritis trials found that the optimal cell preparation and dose remain uncertain. The cell type, how the cells are processed and released, the route of administration and the evidence for your condition matter as much as the number.
Is treatment with my own cells safe?
Autologous cells avoid rejection but do not remove every risk. Reported risks include pain, bruising or infection at the collection site, transient fever or fatigue after infusion, allergic reaction and, rarely, thromboembolic events with intravenous administration. The physician explains the risks that apply to you before you consent.
Start with a clear medical plan, then decide whether Osaka is the right next step
Before deciding whether to travel from Singapore, clarify four things: the expected benefit for your condition, what remains uncertain, the practical arrangements for two visits and the total financial commitment in yen. Send Cell Grand Clinic your medical history and treatment goals through the online consultation page, by WhatsApp or at info@cellgrandclinic.com, have Dr. Wakabayashi assess your case, and then decide — with your doctor in Singapore — whether an in-person assessment in Osaka is the right next step.
Two trips from Singapore, one physician from first email to six-month follow-up.
Autologous stem cell therapy — from JPY 2,970,000 (approx. USD 19,800) per session, 100 million cells, tax included
The fee includes:
- Physician consultation, eligibility screening and blood tests on Visit 1
- Fat-tissue collection under local anaesthesia
- About 7 weeks of individual culture at a licensed cell processing centre · passage ≤3 · ~98% viability · never pooled
- Administration of your cells on Visit 2
- Follow-up at 1 / 3 / 6 months with Dr. Wakabayashi
Final pricing depends on your individual case: cell count, combination protocols and number of sessions. Individual written quotations are provided after the online consultation.
Have Dr. Wakabayashi review your case before you book a flight.
Share your medical history, current treatments and goals. The 60-minute online consultation (JPY 55,000, credited toward treatment) gives you a written assessment, a proposed plan and a quotation in yen — with no obligation to proceed.
References
- Health Sciences Authority (Singapore). Regulatory overview of cell, tissue and gene therapy products. hsa.gov.sg
- Ministry of Health, Labour and Welfare (Japan). Submission of regenerative medicine provision plans under the Act on the Safety of Regenerative Medicine. mhlw.go.jp
- Whittle SL, Johnston RV, McDonald S, et al. Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews 2025;(4):CD013342. doi:10.1002/14651858.CD013342.pub2
- Wakabayashi Y. Symptomatic improvement following intra-articular injection of cultured autologous adipose-derived mesenchymal stem cells in Kellgren-Lawrence grade 3 knee osteoarthritis: a case report with one-year follow-up. Cureus 2026;18(8):e113830. doi:10.7759/cureus.113830
- International Society for Stem Cell Research. Nine things to know about stem cell treatments. aboutstemcells.org
- Ministry of Foreign Affairs of Japan. Exemption of visa (short-term stay). mofa.go.jp
- Centers for Disease Control and Prevention (U.S.). Medical tourism. CDC Yellow Book. cdc.gov
- Cell Grand Clinic. Stem cell therapy cost in Japan (pricing, inclusions, visit schedule and reported risks). cellgrandclinic.com/en/pricing
Medically reviewed by Yuichi Wakabayashi, MD, PhD · Last updated: September 2026
Updated: 2026.09.08
